# Cetuximab and Lenalidomide in Head and Neck

> **NCT01133665** · PHASE2 · COMPLETED · sponsor: **University of Chicago** · enrollment: 42 (actual)

## Conditions studied

- Squamous Cell Carcinoma

## Interventions

- **DRUG:** Cetuximab and Lenalidomide

## Key facts

- **NCT ID:** NCT01133665
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2011-08
- **Final completion:** 2012-08
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2014-11-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01133665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01133665, "Cetuximab and Lenalidomide in Head and Neck". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01133665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*